继发性甲状旁腺功能亢进与高磷血症对CKD进展和心血管事件的独立影响:NEFRONA队列分析
基于NEFRONA队列2445例无既往心血管事件的CKD患者,评估继发性甲状旁腺功能亢进(SHPT)对CKD进展和心血管事件(CVE)的独立影响。中位随访2年301例CKD进展,4年203例CVE;SHPT与高磷血症均为独立危险因素,二者无显著交互作用。
要点
- SHPT患者CKD进展和CVE adjusted风险均显著升高
- 高磷血症是CKD进展和CVE的独立危险因素
- SHPT与高钙或高磷血症间未检出显著交互作用
核心结论
- SHPT和高磷血症均独立与CKD进展及CVE发生相关。
研究设计与样本
- NEFRONA前瞻性队列纳入2445例无既往CVE的CKD患者(3期950例、4期612例、5期195例、透析688例)。
- 采用多因素logistic回归和Fine and Gray回归分析CKD进展与CVE风险。
主要发现
- 队列SHPT患病率65.6%(CKD3期54.7%、4期74.7%、5期71.4%、透析68.6%)。
- 2年内301例患者出现CKD进展,4年随访期间登记203例CVE。
- SHPT患者CKD进展和CVE的调整后风险更高。
- 高磷血症为两种结局的独立危险因素,且不改变SHPT效应。
- SHPT与高钙血症或高磷血症之间未检出显著交互作用。
关键数值与推荐
- SHPT定义为PTH水平过高或正在接受降PTH药物治疗。
临床怎么用
- CKD患者应关注SHPT和高磷血症的独立风险评估。
- 对SHPT或高磷血症患者需同时监测CKD进展和心血管事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD) and is associated with changes in calcium and phosphate. These related changes have been associated with increased cardiovascular mortality and CKD progression. It is not clear whether negative outcomes linked to SHPT are confounded by such factors. The present study was designed to assess the possible independent effects of SHPT [defined as patients with excessive parathyroid hormone (PTH) levels or on treatment with PTH-reducing agents] on the risk of CKD progression and cardiovascular event (CVE) incidence in CKD patients, as well as whether hypercalcaemia and/or hyperphosphataemia act as effect modifiers. METHODS: The study enrolled 2445 CKD patients without previous CVE from the National Observatory of Atherosclerosis in Nephrology (NEFRONA) cohort (Stage 3, 950; Stage 4, 612; Stage 5, 195; on dialysis, 688). Multivariate logistic and Fine and Gray regression analysis were used to determine the risk of patients suffering CKD progression or a CVE. RESULTS: The prevalence of SHPT in the cohort was 65.6% (CKD Stage 3, 54.7%; CKD Stage 4, 74.7%; CKD Stage 5, 71.4%; on dialysis, 68.6%). After 2 years, 301 patients presented CKD progression. During 4 years of follow-up, 203 CVEs were registered. Patients with SHPT showed a higher adjusted risk for CKD progression and CVE. Furthermore, hyperphosphataemia was shown to be an independent risk factor in both outcomes and did not modify SHPT effect. No significant interactions were detected between the presence of SHPT and hypercalcaemia or hyperphosphataemia. CONCLUSIONS: We conclude that SHPT and hyperphosphataemia are independently associated with CKD progression and the incidence of CVE in CKD patients.
引用
- Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant. 2022. PMID: 34021359. doi:10.1093/ndt/gfab184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。